Kopran Limited · NSE:KOPRAN
Kopran — Q4 FY2024-25 Earnings Presentation
22 slides from Kopran's earnings presentation, May 15, 2025
Slide 1: Cover letter to stock exchanges: Investor Presentation
May 15, 2025 The Manager The Manager BSE Limited The National Stock Exchange of India Limited Corporate Relationship Department Exchange Plaza, P. J. Towers, Dalal Street, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 001. Mumbai – 400 051. BSE Scrip Code No. 524280 NSE Symbol : KOPRAN Sub: Inves
Slide 2: Corporate Presentation Q4 FY 2024-25
CORPORATE PRESENTATION Q4 FY 2024-25
Slide 3: This quarterly investor presentation has been prepared by Kopran Limited (‘Kopran’) and does not
This quarterly investor presentation has been prepared by Kopran Limited (‘Kopran’) and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied, should not
Slide 4: Performance
PERFORMANCE • Financial Highlights • Operational Performance • API • Formulation
Slide 5: Financial Highlights
Q-4 Q-3 Q-4 PARTICULARS 2024-25 2023-24 2024-25 2024-25 2023-24 Revenue from Operations 17,236 16,624 18,608 62,960 61,459 EBITDA* 1,709 2,291 2,169 7,290 7,441 Finance Costs 277 216 259 934 859 Depreciation 387 400 359 1,559 1,289 Tax Expenses 403 346 656 1,340 1,659 Net Profit 968 1,040 1,862 3,85
Slide 6: Operational Performance
OPERATIONAL ~ PERF ORMA NCE Kopran
Slide 7: APIs Operational Highlights: Segment-wise Revenue Mix
APIs OPERATIONAL HIGHLIGHTS SEGMENT-WISE REVENUE MIX Q4 FY 2024-25 (Rs. In Lakhs) FY 2024-25 (Rs. In Lakhs) 121 410 73 1056 493 96 1496 1556 Anti- Diabetic 2378 Anti- Diabetic 2383 10 383 Anti- Infective 4767 Anti- Infective 12 2 Anti Lipid Anti-Hypertensive 6200 Antibiotic-Urological Anti-Thromboti
Slide 8: APIs Operational Highlights: Market-wise Revenue Mix
APIs OPERATIONAL HIGHLIGHTS MARKET-WISE REVENUE MIX Q4 FY 2024-25 (Rs. In Lakhs) FY 2024-25 (Rs. In Lakhs) 15935 4613 Export Sales Export Sales Local Sales Local Sales 5097 19946 Total Rs. 9,710 Lakhs Total Rs. 35,881 Lakhs
Slide 9: Formulations Operational Highlights: Region-wise Sales Break-up
Formulations OPERATIONAL HIGHLIGHTS REGION-WISE SALES BREAK-UP Q4 FY 2024-25 (Rs. In Lakhs) FY 2024-25 (Rs. In Lakhs) 769 2841 384 7232 2148 Africa 2357 Africa Canada Middle East and North Africa Latem South Africa Middle East and North Africa 127 South Africa Southeast Asia 633 Southeast Asia UK UK
Slide 10: Formulations Operational Highlights: Product-wise Revenue Mix
Formulations OPERATIONAL HIGHLIGHTS PRODUCT-WISE REVENUE MIX Q4 FY 2024-25 (Rs. In Lakhs) FY 2024-25 (Rs. In Lakhs) 2824 11621 Non Pen Plant Non Pen Plant Pen Plant Pen Plant 4403 14628 Total Rs. 7,227 Lakhs Total Rs. 26,249 Lakhs
Slide 11: Company Overview
Company Overview • About Us • Business Overview – API • Business Overview – Formulations • Driving Sustainable Growth
Slide 12: A Global Pharmaceutical Company
A GLOBAL PHARMACEUTICAL COMPANY An integrated Pharmaceutical Company, committed to supplying International 50+ Quality Formulations and Active Pharmaceutical Ingredients (APIs) globally. Nations - Export Reach State-of-the-art manufacturing facilities and products with various accreditations and app
Slide 13: API Vertical
API API DEDICATED AND VERSATILE PRODUCT VERTICAL FACILITIES FOR SEGMENT Anti-hypertensive Development, manufacturing and Atenolol Macrolide sale of diverse APIs and Advanced Neuromodulator Intermediates Cephalosporins - Non-Sterile & Sterile Urological One of the leaders in Atenolol
Slide 14: Formulations Vertical: Product Segments
FORMULATIONS PRODUCT SEGMENTS FORMULATIONS VERTICAL Development and manufacturing of oral solid dosages and dry powder formulations for both Penicillin- and Non-Penicillin-based drugs PENICILLIN-BASED NON-PENICILLIN FINISHED ORAL BASED FINISHED Catering 100% export markets of both Regulated and
Slide 15: Strategic Imperatives
STRATEGIC IMPERATIVES GROWTH AND SUSTAINABILITY COST LEADERSHIP Focus on R&D to develop niche, Development of intermediates for APIs high-value/high-volume APIs and intermediates Reducing dependence on China to move towards self sufficiency Capacity expansion Optimising operational cost
Slide 16: Regulatory Compliance
REGULATORY COMPLIANCE OFFERING BEST-IN-CLASS QUALITY THROUGH STRICT COMPLIANCE The Company maintains highest global regulatory standards FORMULATIONS ACCREDITATIONS of manufacturing and quality at its all plants API ACCREDITATIONS Approved by 15 countries including MHRA (UK), SAPHRA South The plant
Slide 17: Kopwan
~ Kopwan 900()!--====--=---=--=:.::.:_ _~- 00() ..,.___ OOo ----------
Slide 18: Snapshot
SNAPSHOT SALES/OTHER INCOME (Rs. LAKHS) EBITDA * (Rs. LAKHS) 8,739 8,178 62,920 63,359 7,441 7,290 55,405 50,980 48,813 5,180 36,013 4,696 2019-20 2020-21 2021-22 2022-23 2023-24 2024-25 2019-20 2020-21 2021-22 2022-23 2023-24 2024-25 FINANCE COSTS (Rs. LAKHS) NET PROFIT/(LOSS) (Rs. LAKHS) 934 891 8
Slide 19: Building Shareholder Value Year on Year
BUILDING SHAREHOLDER VALUE YEAR ON YEAR EBITDA ( Rs. Lakhs) RoE ( % ) RoCE ( % ) 28.3 8,739 25.3 8,178 7,441 22.4 7,290 20.1 5,180 14.5 4,996 11.4 11.8 10.1 8.3 11 7.6 6.3 2019-20 2020-21 2021-22 2022-23 2023-24 2024-25 2019-20 2020-21 2021-22 2022-23 2023-24 2024-25 - Return on Networth/Equity - Re
Slide 20: Six-year financial summary (Rs. Lakhs)
(Rs. Lakhs) PARTICULARS FY 2024-25 FY 2023-24 FY 2022-23 FY 2021-22 FY 2020-21 FY 2019-20 Equity Share Capital 4,829 4,821 4,821 4,821 4,325 4,325 Other Equity 47,006 44,303 39,104 37,796 20,178 14,643 Networth 51,835 49,125 43,925 42,617 24,503 18,968 Fixed Assets(net) 32,160 27,830 23,457 18,623 1
Slide 21: Board of Directors
BOARD OF DIRECTORS MR. SURENDRA SOMANI MR. ADARSH RAJENDRA SOMANI MRS. MAMTA BIYANI MR. NARAYAN ATAL EXECUTIVE VICE CHAIRMAN DIRECTOR INDEPENDENT DIRECTOR INDEPENDENT DIRECTOR DR. SIDDHAN SUBRAMANIAN DR. SUNITA BANERJI MR. SUSHEEL SOMANI MR. VARUN SURENDRA SOMANI INDEPENDENT DIRECTOR INDEPENDENT DIR
Slide 22: About Kopran Limited
ABOUT KOPRAN LIMITED: Kopran Limited is an integrated Pharmaceutical Company, committed to manufacturing and supplying International Quality Formulations and APIs worldwide. Kopran's manufacturing facilities and products have accreditations across all the continents. Research & Development for New P